January 2015
StoneCalibre is pleased to announce that its portfolio company, Anatrace, has completed the acquisition of Microlytic, a provider of innovative life science tools and reagents to the structural biology market.
StoneCalibre is pleased to announce that its portfolio company, Anatrace, has completed the acquisition of Microlytic, a provider of innovative life science tools and reagents to the structural biology market. Microlytic’s solutions represent the most productive approaches to soluble protein crystallization, which allow researchers to accelerate workflow, increase output quality and help solve the major problem in structural biology: crystal formation.
“Microlytic will add to Anatrace’s market leading portfolio of high-purity detergents and synthetic lipids, including the co-developed Analytic product line,” said Brian Wall, Founder and Chief Executive Officer of StoneCalibre. “We will continue to look for strategic acquisitions, such as Microlytic, to supplement Anatrace’s organic growth and as a means to broaden our product offering and expand our customer base.”
Dr. Ben Travis, CEO of Anatrace, expressed his enthusiasm for the transaction. “We have been impressed by the Microlytic team and their track record of innovation in the structural biology market and look forward to working together towards achieving the high standards that have come to define Anatrace.” Dr. Travis stated, “With the acquisition of Microlytic we are able to deliver a comprehensive and innovative set of solutions that will further advance the important field of protein biology research.”